About Liquidia
PRINT Technology
Pipeline
Investors
Newsroom
Careers
Contact Us
About Liquidia
PRINT Technology
Pipeline
Investors
Newsroom
Careers
Contact Us
What if you could engineer uniform drug particles to improve the patient experience?
Liquidia can.
Imagine designing drug products without constraints...
Liquidia does.
What if you could replace five formulation platforms with one?
Our PRINT Technology does.
Pipeline
Advancing Product Candidates

from Our Own Pipeline
LEARN MORE
PRINT
®
 Technology
A Simple Elegant Solution for Addressing Challenges in Drug Delivery
LEARN MORE
Strategic Collaborations
Actively Partnering with

World-class Collaborators
CONTACT US
Liquidia Technologies
 is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary 
PRINT technology
 to transform the lives of patients. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own 
pipeline
: 
LIQ861
 for the treatment of pulmonary arterial hypertension (PAH) and 
LIQ865
 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types and routes of administration.
LEARN MORE
Recent News
 Liquidia Technologies to Present at Jefferies London Healthcare Conference
 Liquidia Technologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Events and Presentations
November 15, 2018 07:40:00 AM EST
 Jefferies London Healthcare Conference
Improving health with uniform drug particles
Liquidia precisely engineers drug particles in a virtually unlimited number of ways to transform the lives of patients. Watch the video to see how we do it. The precision of our PRINT technology is designed to improve the safety, efficacy and performance of a wide range of therapies, while reducing manufacturing complexity and cost.
Home
About Liquidia
— Leadership
— Board of Directors
— Collaborations
— Business Development
PRINT Technology
— Publications
Pipeline
— LIQ861
— LIQ865
Investors
Newsroom
© 2018 Liquidia Technologies
Legal
Privacy
Cookies
Social Media